Clinical Trials Browser

Phase 3 × Erlotinib Hydrochloride × 30 days × Clear all

NCT02296125 2026-04-21

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT02193282 2026-04-13

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung